Corbus Pharmaceuticals Holdings Inc $ 1.95 -0.02 (-1.02%)
Warning! GuruFocus has detected 5 Severe warning signs with CRBP. Click here to check it out.
Avg Vol (1m):
Market Cap $:
Enterprise Value $:
Current and historical daily P/E ratio for Corbus Pharmaceuticals Holdings Inc () from 2014 to Jan 28 2021. The price to earnings ratio is calculated by taking the current stock price and dividing it by the most recent trailing twelve-month earnings per share (EPS) number. The data is updated every 20 minutes during market hours. The P/E ratio can be viewed as the number of years it takes for the company to earn back the price you pay for the stock. Therefore, lower-P/E stocks are more attractive than higher P/E stocks so long as the P/E ratio is positive. Also for stocks with the same P/E ratio, the one with faster growth business is more attractive. Corbus Pharmaceuticals stock (CRBP) PE ratio as of Jan 28 2021 is 0. More Details
Corbus Pharmaceuticals PE Ratio (TTM) Historical Data
View and export this data going back to 2014. Start your Free Trial
Corbus Pharmaceuticals PE Ratio (TTM) Comparison
|Company||Market Cap(Mil)||PE Ratio (TTM)|
Compare NAS:SRRK NAS:CLVS NAS:MGTX NAS:PRVL NAS:VNDA NAS:ATHX NAS:HARP NAS:STML NAS:CRNX NAS:NERV OCSE:NOVO B ASX:CSL NAS:VRTX NAS:REGN XKRX:207940 NAS:SGEN NAS:MRNA NAS:ALXN XKRX:068270 NAS:INCY
Address 500 River Ridge Drive, Second Floor, Norwood, MA, USA, 02062
Corbus Pharmaceuticals Holdings Inc is a Phase 3 clinical-stage pharmaceutical company focused on the development and commercialization of novel therapeutics to treat rare, chronic, and serious inflammatory and fibrotic diseases. The company's lead product candidate, lenabasum, is a novel, synthetic oral endocannabinoid-mimetic drug designed to resolve chronic inflammation and fibrotic processes. Lenabasum is currently being evaluated in systemic sclerosis, cystic fibrosis, dermatomyositis, and systemic lupus erythematosus.